Delayed Onset of Thrombotic Microangiopathy (TMA) upon Prolonged Carfilzomib Therapy in Multiple Myeloma: A Case Report and Comprehensive Review

Delayed Onset of Thrombotic Microangiopathy (TMA) upon Prolonged Carfilzomib Therapy in Multiple Myeloma: A Case Report and Comprehensive Review

Background: Thrombotic microangiopathy (TMA) is a potentially life-threatening complication associated with carfilzomib, a proteasome inhibitor approved for treating multiple myeloma. TMA typically presents within the initial months of treatment; however, delayed onset is rare and poses significant...

Full description

Saved in:
Bibliographic Details
Main Authors: Andrea Ceglédi, Ágnes Király, Andrea Várkonyi, Szabolcs Tasnády, Hajnalka Andrikovics, Mónika Fekete, Bálint G. Szabó, Zsuzsanna Szemlaky, Ágnes Szilágyi, György Sinkovits, Zoltán Prohászka, Marienn Réti, Gábor Mikala
Format: Article
Language:English
Published: MDPI AG 2024-12-01
Series:Pharmaceuticals
Subjects:
thrombotic microangiopathy
carfilzomib
multiple myeloma
plasmapheresis
delayed onset
Online Access:https://www.mdpi.com/1424-8247/17/12/1722
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.mdpi.com/1424-8247/17/12/1722

Similar Items